BACKGROUND: Merkel cell carcinoma is a rare malignancy of the skin. Integration of Merkel cell polyomavirus (MCPyV) DNA to the tumor genome is frequent in these cancers. The clinical consequences of MCPyV infection are unknown. METHODS: We analyzed formalin-fixed paraffin-embedded Merkel cell carcinoma tissue samples from 114 of 207 patients diagnosed with Merkel cell carcinoma in Finland from 1979 to 2004 for the presence of MCPyV DNA with the use of polymerase chain reaction (PCR), quantitative PCR, and DNA sequencing and examined associations between tumor MCPyV DNA status and histopathologic factors and survival. The median follow-up time after Merkel cell carcinoma diagnosis for subjects who were alive was 9.9 years (range = 4.9-21.9 years). All P values are two-sided. RESULTS: MCPyV DNA was present in 91 carcinomas (79.8%). Compared with MCPyV DNA-negative cancers, MCPyV DNA-positive cancers were more often located in a limb (40.7% vs 8.7%, P = .015) and less frequent in patients who had regional nodal metastases at diagnosis (6.6% vs 21.7%, P = .043). Patients with MCPyV DNA-positive tumors had better overall survival than those with MCPyV DNA-negative tumors (5-year survival: 45.0% vs 13.0%, respectively; P < .001, two-sided log-rank test). CONCLUSIONS: MCPyV infection is associated with clinical outcomes in patients with Merkel cell carcinoma. These findings lend support to the hypothesis that viral infection is frequently associated with the pathogenesis of Merkel cell carcinoma.
BACKGROUND:Merkel cell carcinoma is a rare malignancy of the skin. Integration of Merkel cell polyomavirus (MCPyV) DNA to the tumor genome is frequent in these cancers. The clinical consequences of MCPyVinfection are unknown. METHODS: We analyzed formalin-fixed paraffin-embedded Merkel cell carcinoma tissue samples from 114 of 207 patients diagnosed with Merkel cell carcinoma in Finland from 1979 to 2004 for the presence of MCPyV DNA with the use of polymerase chain reaction (PCR), quantitative PCR, and DNA sequencing and examined associations between tumorMCPyV DNA status and histopathologic factors and survival. The median follow-up time after Merkel cell carcinoma diagnosis for subjects who were alive was 9.9 years (range = 4.9-21.9 years). All P values are two-sided. RESULTS:MCPyV DNA was present in 91 carcinomas (79.8%). Compared with MCPyV DNA-negative cancers, MCPyV DNA-positive cancers were more often located in a limb (40.7% vs 8.7%, P = .015) and less frequent in patients who had regional nodal metastases at diagnosis (6.6% vs 21.7%, P = .043). Patients with MCPyV DNA-positive tumors had better overall survival than those with MCPyV DNA-negative tumors (5-year survival: 45.0% vs 13.0%, respectively; P < .001, two-sided log-rank test). CONCLUSIONS:MCPyVinfection is associated with clinical outcomes in patients with Merkel cell carcinoma. These findings lend support to the hypothesis that viral infection is frequently associated with the pathogenesis of Merkel cell carcinoma.
Authors: Stephanie K Demetriou; Katherine Ona-Vu; Erin M Sullivan; Tiffany K Dong; Shu-Wei Hsu; Dennis H Oh Journal: Int J Cancer Date: 2012-05-29 Impact factor: 7.396
Authors: Valentina Nardi; Youngchul Song; Juan A Santamaria-Barria; Arjola K Cosper; Quynh Lam; Anthony C Faber; Genevieve M Boland; Beow Y Yeap; Kristin Bergethon; Vanessa L Scialabba; Hensin Tsao; Jeffrey Settleman; David P Ryan; Darrell R Borger; Atul K Bhan; Mai P Hoang; Anthony J Iafrate; James C Cusack; Jeffrey A Engelman; Dora Dias-Santagata Journal: Clin Cancer Res Date: 2012-01-18 Impact factor: 12.531
Authors: Jayasri G Iyer; Barry E Storer; Kelly G Paulson; Bianca Lemos; Jerri Linn Phillips; Christopher K Bichakjian; Nathalie Zeitouni; Jeffrey E Gershenwald; Vernon Sondak; Clark C Otley; Siegrid S Yu; Timothy M Johnson; Nanette J Liegeois; David Byrd; Arthur Sober; Paul Nghiem Journal: J Am Acad Dermatol Date: 2014-02-09 Impact factor: 11.527
Authors: T Gambichler; S Mohtezebsade; U Wieland; S Silling; A-K Höh; M Dreißigacker; J Schaller; H-J Schulze; F Oellig; A Kreuter; E Stockfleth; M Stücker; F G Bechara; J C Becker Journal: J Cancer Res Clin Oncol Date: 2016-09-13 Impact factor: 4.553